MIM
RCUS icon

Macroview Investment Management’s Arcus Biosciences RCUS Stock Holding History

Macroview Investment Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-115
Closed -$1.76K – 432
2024
Q3 		$1.76K Hold
115
– – ﹤0.01% 492
2024
Q2 		$1.75K Hold
115
– – ﹤0.01% 493
2024
Q1 		$2.17K Sell
115
-408
-78% -$7.05K ﹤0.01% 531
2023
Q4 		$9.99K Buy
523
+5
+1% +$80 0.01% 260
2023
Q3 		$9.3K Buy
+518
New +$10.4K 0.01% 286

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

Macroview Investment Management's RCUS Position: Q4 2024 in Review

Macroview Investment Management sold out of Arcus Biosciences (RCUS) in Q4 2024, closing a stake of 115 shares — an estimated $1.76K sold.

Macroview Investment Management first reported a position in RCUS in Q3 2023 and held it in 5 quarters. The position peaked at $9.99K in Q4 2023. 186 funds tracked by Wall St. Rank hold RCUS as of Q4 2024.

  • Macroview Investment Management reported no remaining Arcus Biosciences position as of Q4 2024 after selling out during the quarter.
  • Macroview Investment Management sold 115 Arcus Biosciences shares in Q4 2024, an estimated $1.76K.
  • Macroview Investment Management first reported a position in Arcus Biosciences in Q3 2023 and held it in 5 quarters.
  • Macroview Investment Management's Arcus Biosciences position peaked at $9.99K in Q4 2023.
  • 186 funds tracked by Wall St. Rank held Arcus Biosciences as of Q4 2024.

Based on Macroview Investment Management's 13F filing for Q4 2024, filed 31 Jan 2025.